| ²é¿´: 4815 | »Ø¸´: 3 | ||
ÂÞÈýÅÚ½ð³æ (ÖøÃûдÊÖ)
|
[ÇóÖú]
top-line results ÊÇʲôÒâ˼£¿ ÒÑÓÐ3È˲ÎÓë
|
|
ÇóÖú£ºÒÔÏÂÖеÄtop-line results ÊÇʲôÒâ˼£¿ Pfizer Inc. (NYSE FE) today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer (NSCLC).http://www.pfizer.com/news/press ... ll_cell_lung_cancer |
» ²ÂÄãϲ»¶
ÇóÖú·ëÁ¬·¼¡¢ÕŲÅÁÁµÄ¡¶¾ÛºÏ¹ý³ÌÇ¿»¯¼¼Êõ¡·
ÒѾÓÐ1È˻ظ´
2026¿¼²©
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ233È˻ظ´
Õã½ÖÐÒ½Ò©´óѧÕÅÓÂÃñԺʿ2026Ä격ʿÑо¿ÉúÕÐÉú
ÒѾÓÐ3È˻ظ´
ÁòÃÑÑõ»¯
ÒѾÓÐ2È˻ظ´
26²©Ê¿ÉêÇë-Ò©Îﻯѧ·½Ïò
ÒѾÓÐ32È˻ظ´
ÇóÖúcortellisÊý¾Ý¿â²éѯÕë¶Ô°ÐµãABCC6µÄÒ©ÎïºÍÔÚÑзÖ×Ó
ÒѾÓÐ1È˻ظ´
Õ»۵ȱàÖøµÄ¡¶Åäλ»¯Ñ§£ºÔÀíÓëÓ¦Óá·
ÒѾÓÐ1È˻ظ´
ÇóÖú£¡£¡£¡´óÀоÈÃü£¡£¡£¡
ÒѾÓÐ4È˻ظ´
õ£°·ËõºÏ
ÒѾÓÐ3È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
B-stagedÊÇʲôÒâ˼£¿
ÒѾÓÐ3È˻ظ´
ÇëÎÊһϸ÷룬p-TLCÊÇʲôÒâ˼£¿
ÒѾÓÐ4È˻ظ´
tg-1ÊÇʲôÒâ˼°¡£¿
ÒѾÓÐ3È˻ظ´
ÇëÎÊlabel-free detection ÊÇʲôÒâ˼£¿
ÒѾÓÐ4È˻ظ´
Photo-FentonÊÇʲôÒâ˼£¿
ÒѾÓÐ6È˻ظ´
melt-spinning ÊÇʲôÒâ˼£¿Ïà¹ØµÄÎÄÕÂÒÑÉÏ´«
ÒѾÓÐ8È˻ظ´
flame-sealedÊÇʲôÒâ˼£¿ÓÐÒÀ¾ÝµÄ½øÀ´
ÒѾÓÐ2È˻ظ´
1000aÊÇʲôÒâ˼£¿
ÒѾÓÐ9È˻ظ´
free-standing batteryÊÇʲôÒâ˼£¿
ÒѾÓÐ6È˻ظ´
ÇëÎÊ the top of the figure indicatedÊÇʲôÒâ˼°¡£¿
ÒѾÓÐ16È˻ظ´
ABCÊÇʲôÒâ˼£¿
ÒѾÓÐ15È˻ظ´
MÊÇʲôÒâ˼£¿
ÒѾÓÐ29È˻ظ´
c12/c1ÊÇʲôÒâ˼£¿
ÒѾÓÐ3È˻ظ´
half-pitch resolutionÊÇʲôÒâ˼£¿
ÒѾÓÐ3È˻ظ´
Çë°ïæ¿´¿´Õâ¾ä»°Ê²Ã´Òâ˼ Sub title under Materials and Methods or Results and Di
ÒѾÓÐ5È˻ظ´
ÂÛÎÄͶ¸åÖÐ image "top" should be indicated. ÊÇʲôÒâ˼°¡
ÒѾÓÐ3È˻ظ´
ÎÊauthor guidelineÀïÒ»¸öÒªÇówith line numbering ÊÇʲôÒâ˼£¿
ÒѾÓÐ7È˻ظ´
Õâ¸öÊÇʲôÒâ˼£¿
ÒѾÓÐ8È˻ظ´
Ó¢ÓïÃû´Ê½âÊÍ¡£¡£¡£moving three-phase contact line ÊÇʲôÒâ˼
ÒѾÓÐ6È˻ظ´
line figureÊÇʲôÒâ˼
ÒѾÓÐ4È˻ظ´
pre-headingÊÇʲôÒâ˼£¿
ÒѾÓÐ4È˻ظ´
Õâ¸öÊÇʲôÒâ˼£¿
ÒѾÓÐ14È˻ظ´
Camera-readyÊÇʲôÒâ˼£¿
ÒѾÓÐ15È˻ظ´
Artwork Quality Results ״̬À¸ÖеÄN/AÊÇʲôÒâ˼°¡£¡
ÒѾÓÐ7È˻ظ´
kdl0721
½ð³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 76 (³õÖÐÉú)
- ½ð±Ò: 528.3
- É¢½ð: 69
- ºì»¨: 30
- Ìû×Ó: 1047
- ÔÚÏß: 319Сʱ
- ³æºÅ: 1246356
- ×¢²á: 2011-03-27
- רҵ: ÎÞ»ú·Ç½ðÊô»ù¸´ºÏ²ÄÁÏ
2Â¥2015-04-03 13:20:14
purongzhen
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 11 (СѧÉú)
- ½ð±Ò: 2659.1
- É¢½ð: 1736
- ºì»¨: 3
- Ìû×Ó: 670
- ÔÚÏß: 250.1Сʱ
- ³æºÅ: 1218146
- ×¢²á: 2011-03-02
- ÐÔ±ð: GG
- רҵ: Ò©¼Áѧ
3Â¥2015-04-03 13:53:20
kwindmark
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 9 (Ó×¶ùÔ°)
- ½ð±Ò: 950.6
- Ìû×Ó: 127
- ÔÚÏß: 117.1Сʱ
- ³æºÅ: 1540956
- ×¢²á: 2011-12-17
- ÐÔ±ð: GG
- רҵ: Ò©Îï¶¾Àí
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
ÂÞÈýÅÚ: ½ð±Ò+6, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, ·Ç³£²»´í£¡Ð»Ð»£¡ 2015-04-03 19:20:57
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
ÂÞÈýÅÚ: ½ð±Ò+6, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, ·Ç³£²»´í£¡Ð»Ð»£¡ 2015-04-03 19:20:57
|
¡°Top-line Results¡± is a statistical term of art. It is analogous to ¡°Bottom-line Results¡± as a finance term of art. In other words, Top-line Results are the outcomes of the analyses (e.g., totals, frequencies, distributions or marginals) that are the output of a statistical analysis ¨C whether that analysis is based on preliminary data or final data. In the clinical arena, Top-line Results (regardless of the stage of the trial or the phase of the trial) speak to the statistical significance of the trial results coming out of the subject population. Pharma often cites Top-line Results as the basis for its decision to terminate a trial or to continue a trial. |
4Â¥2015-04-03 14:47:55













FE) today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer (NSCLC).
»Ø¸´´ËÂ¥